

Kent Academic Repository

Merlini, M, Whyte, Greg, Chester, Neil, Loosemore, Mike, Marcora, Samuele Maria and Dickinson, John W. (2016) *The Long-Term Ergogenic Effect of Long Acting ?2-Agonists.* In: 21st Annual Congress of European College of Sport Science, 6th – 9th July, 2016, Vienna.

Downloaded from

https://kar.kent.ac.uk/57168/ The University of Kent's Academic Repository KAR

The version of record is available from

This document version

Presentation

DOI for this version

Licence for this version UNSPECIFIED

Additional information

Versions of research works

Versions of Record

If this version is the version of record, it is the same as the published version available on the publisher's web site. Cite as the published version.

Author Accepted Manuscripts

If this document is identified as the Author Accepted Manuscript it is the version after peer review but before type setting, copy editing or publisher branding. Cite as Surname, Initial. (Year) 'Title of article'. To be published in *Title of Journal*, Volume and issue numbers [peer-reviewed accepted version]. Available at: DOI or URL (Accessed: date).

Enquiries

If you have questions about this document contact ResearchSupport@kent.ac.uk. Please include the URL of the record in KAR. If you believe that your, or a third party's rights have been compromised through this document please see our Take Down policy (available from https://www.kent.ac.uk/guides/kar-the-kent-academic-repository#policies).









Long term β_2 -Agonists administration increases sprint performance in non-asthmatics

Merlini M¹, Whyte G², Chester N², Loosemore M³, Marcora S¹, Dickinson J¹,

¹ Endurance Research Group University of Kent, ² RISES, Liverpool John Moores University, ³ University College of London







AIM OF THE STUDY

Investigate the ergogenic effect of 5 weeks daily inhalation of long acting β_2 -Agonists on Sprint performance.

METHODS

Participants: 23 and 12 non asthmatic males and females

Design: Blind, Randomised, Counter balanced training study

Treatment groups:

- Salmeterol (SAL) 100µg (2 x 50µg twice daily) n=12
- Formoterol (FOR) 12μg (2 x 6μg twice daily) n=12
- Placebo (PLA) (2 x twice daily) n=11

30 mt Sprint

Strength and Power Training

30 mt Sprint

Week 6








Table 1: Change in 30 m sprint from week 0 to week 5

Figure 1: Change in 30 m sprint from week 0 to week 5

	Week 0	Week 5
SAL	$7.38 \pm 0.74 \text{ s}$	$7.03 \pm 0.72 \text{ s}$
FOR	$7.10 \pm 0.70 \text{ s}$	$6.81 \pm 0.74 \text{ s}$
PLA	7.40 ± 1.33 s	$7.40 \pm 1.23 \text{ s}$



30m Sprint was greater 5 weeks post training in FOR (p=0.049) and SAL (p=0.040) compared to PLA.







CONCLUSION

- Sprint improvement observed over 5 weeks did not differ between SAL and FOR groups. However, FOR and SAL showed a significant improvement in sprint performance when compared with PLA following the 5 weeks of strength training.
- SAL and FOR may increased anaerobic ATP utilization, elevated glycolytic activity and enhanced rates of Ca²⁺ release and uptake from the sarcoplasmic reticulum.
- Future research should investigate potential mechanisms to explain our results.